-
Pfizer shares positive five-year results for Lorbrena in advanced lung cancer
03 Jun 2024 11:21 GMT
… in advanced non-small cell lung cancer (NSCLC).
The phase 3 … Pfizer’s tyrosine kinase inhibitor Xalkori (crizotinib) in patients … ALK-positive advanced NSCLC.”
Lung cancer is the number one … a remarkable advancement in lung cancer.”
The company has also …
-
New lung cancer pill produces “unprecedented” results in human trial
03 Jun 2024 08:59 GMT
… including non-small cell lung cancer (NSCLC), causing the cancer … types of lung cancer – the other is small cell lung cancer – NSCLC … ALK inhibitor sold as Xalkori. Lorlatinib is given as … represent a remarkable advancement in lung cancer,” said Solomon.
The …
-
Pfizer's Lorbrena CROWN study shows majority of patients with ALK─positive advanced lung cancer living beyond five years without disease progression
03 Jun 2024 06:17 GMT
… brand name Lorviqua) versus Xalkori (crizotinib) in people with … advanced non-small cell lung cancer (NSCLC). After five years … approximately 80-85% of lung cancers, with ALK-positive tumours … a remarkable advancement in lung cancer.”
In this updated analysis …
-
Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer
01 Jun 2024 23:00 GMT
… -positive metastatic non-small-cell lung cancer (NSCLC), according to study results … . Genetic testing can show whether lung tumors carry driver mutations, such as … drugs in this class include Xalkori (crizotinib), Zykadia (ceritinib), Alecensa (alectinib …
-
Pfizer Expects Lung Cancer Drug Lorbrena to Hit Over $1 Billion in Sales After Exceptional 5-Year Data
01 Jun 2024 14:13 GMT
Pfizer has announced that its lung cancer drug, Lorbrena, is projected … a rare form of advanced lung cancer in a clinical trial … Pfizer's earlier drug, Xalkori.
Results from the company… 8% for those treated with Xalkori.
Additionally, 53% of Lorbrena …
-
Lorlatinib produces ‘unprecedented’ disease progression delay in ALK-positive lung cancer
31 May 2024 23:02 GMT
… adults with ALK-mutant advanced lung cancer compared with crizotinib.
Researchers reported … brain metastases compared with crizotinib (Xalkori, Pfizer).
Data derived from … magnitude.”
Background and methodology
Lung cancer causes more cancer-related deaths …
-
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer
31 May 2024 18:37 GMT
… in Europe as Lorviqua versus Xalkori (crizotinib) in people with … )-positive advanced non-small cell lung cancer (NSCLC).
Also Read: Pfizer … or death rate compared to Xalkori.
Further, 60% of patients … to 5% of patients receiving Xalkori.
The safety profiles of …
-
STAT+: For one rare type of lung cancer, Pfizer pill reduces progression by 81%
31 May 2024 13:48 GMT
… treatment for non-small cell lung cancer, might not seem to be … . The medicine, for patients whose lung tumors have particular genetic mutations, generated … an inert placebo but to Xalkori, another Pfizer targeted cancer drug …
-
Pfizer's drug for advanced lung cancer shows promising long-term trial results
31 May 2024 13:13 GMT
… an advanced form of lung cancer showed promising long-term … that specific form of lung cancer each year worldwide, according … Pfizer's older lung cancer drug Xalkori. At the five-year … 39;s Lorbrena with competing lung cancer drugs, including one called …
-
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
31 May 2024 13:01 GMT
… -positive patients with advanced lung cancer who were treated with … a very different opportunity than Xalkori," which never reached … 4% of non-small cell lung cancer (NSCLC) patients globally have … most common type of lung cancer. Boshoff also noted that …